What are the suitable anti-diabetic (DM) medications for a patient with acute kidney injury (AKI) and diabetes mellitus (DM)?

Anti-Diabetic Medications for Acute Kidney Injury (AKI)

In patients with diabetes and AKI, insulin is the safest and most appropriate glucose-lowering agent, while metformin, SGLT2 inhibitors, and sulfonylureas should be discontinued immediately until kidney function stabilizes.

Immediate Management: Medications to STOP During AKI

Metformin - DISCONTINUE

• Metformin must be withdrawn immediately in AKI due to increased risk of lactic acidosis from impaired renal excretion 1
• Stop metformin during any acute illness causing dehydration or when administering nephrotoxic drugs 2
• Metformin-associated lactic acidosis most commonly occurs concurrent with acute illness when AKI contributes to reduced clearance 1

SGLT2 Inhibitors - DISCONTINUE

• Withhold SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) during AKI to prevent volume depletion and euglycemic diabetic ketoacidosis 3
• SGLT2 inhibitors should be held during acute illness, particularly with reduced food/fluid intake, fever, vomiting, or diarrhea 3
• These agents cause natriuresis and intravascular volume contraction that can worsen renal hypoperfusion in AKI 4

Sulfonylureas - DISCONTINUE

• Professional societies recommend against sulfonylurea use in hospitalized patients due to sustained hypoglycemia risk, especially with variable oral intake 5, 6
• Most sulfonylureas must be discontinued when GFR <60 mL/min/1.73 m² 2
• Sulfonylureas have active metabolites that accumulate in renal impairment, significantly increasing severe hypoglycemia risk 6

RAS Inhibitors - REDUCE DOSE OR WITHDRAW

• ACE inhibitors and ARBs should be reduced or withdrawn in patients who develop AKI 7
• Continue monitoring serum creatinine; if it increases >30% within 4 weeks, reduce dose or stop the agent 8
• RAS inhibitors can worsen AKI through impaired autoregulation and potentiation of hypotension-induced kidney injury 4

Safe Medications During AKI

Insulin - PREFERRED AGENT

• Insulin remains effective regardless of kidney function and is the safest option for glycemic control during AKI 3
• Insulin can be dose-adjusted based on clinical response without concern for drug accumulation 3
• Maintain at least low-dose insulin in insulin-requiring patients even when other agents are held 3
• Target glucose 140-180 mg/dL in hospitalized patients with AKI to reduce hypoglycemia risk 9

DPP-4 Inhibitors - USE WITH CAUTION

• Linagliptin is the only DPP-4 inhibitor that requires no dose adjustment in any degree of renal impairment, including AKI 5, 10, 2
• Linagliptin has only 5% renal elimination and can be continued at 5 mg daily regardless of kidney function 10, 11
• Other DPP-4 inhibitors (sitagliptin, saxagliptin) require dose reduction based on eGFR and should be adjusted or held during AKI 5, 2
• However, exercise caution when using linagliptin with ACE inhibitors in AKI, as the combination may potentiate renal hypoperfusion 4
• Monitor kidney function closely when initiating linagliptin in combination with ACE inhibitors in patients with preexisting kidney disease 4

Clinical Algorithm for AKI Management

Step 1: Immediate Assessment

• Identify and discontinue nephrotoxic medications: metformin, SGLT2 inhibitors, sulfonylureas 1, 3, 2
• Assess volume status and correct dehydration before considering any oral agents 3
• Check for concurrent use of ACE inhibitors/ARBs and consider dose reduction 7

Step 2: Glucose Management Strategy

• Transition to insulin therapy as primary glucose-lowering agent during acute phase 3
• If patient requires oral agent and eGFR stabilizes >30 mL/min/1.73 m², linagliptin 5 mg daily may be considered 5, 10
• Avoid tight glucose control (80-110 mg/dL); target 140-180 mg/dL to prevent hypoglycemia 9

Step 3: Monitoring During AKI

• Monitor serum creatinine and eGFR at least every 2-4 weeks during AKI recovery 8
• Check serum potassium levels if continuing ACE inhibitors/ARBs 8
• Assess for hypoglycemia risk, which is significantly increased in AKI due to reduced insulin clearance 9

Step 4: Medication Reintroduction After AKI Resolution

• Do not restart metformin until eGFR stabilizes ≥30 mL/min/1.73 m² for at least 3 months 1
• SGLT2 inhibitors can be restarted when eGFR ≥25 mL/min/1.73 m² and patient is clinically stable 3
• Sulfonylureas should generally be avoided; consider alternative agents with lower hypoglycemia risk 5, 6

Critical Pitfalls to Avoid

• Never continue metformin during AKI regardless of baseline kidney function - lactic acidosis risk is substantially elevated 1, 2
• Do not assume DPP-4 inhibitors are interchangeable in AKI - only linagliptin requires no dose adjustment 5, 10
• Avoid combining linagliptin with ACE inhibitors during AKI initiation - this may worsen renal hypoperfusion through additive natriuretic effects 4
• Do not pursue tight glycemic control in AKI - hypoglycemia risk is markedly increased due to reduced insulin and drug clearance 9
• Never restart SGLT2 inhibitors during active AKI - wait until kidney function stabilizes to prevent volume depletion and ketoacidosis 3